"/> Tocris Bioscience™ JB 300 | B-LABO France

Tocris Bioscience™ JB 300

Réf. : BL-RE-157979Réf. fabricant : 18706025 5 mg
393,08 € HT

Aurora A Degrader (PROTAC™;)

Nom chimique ou matériau
trans-4-(3-Chloro-2-fluorophenoxy)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethoxy)ethyl)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxamide
Quantité
5 mg
Cible
Active Degraders
Formule moléculaire
C43H45ClFN7O10S
Pureté
0.98
Marque
Tocris Bioscience

JB 300 is a potent and selective Aurora A Degrader (PROTAC™;; DC50 = 30 nM and Dmax = 78%). It comprises a cereblon E3-ligase ligand Thalidomide (Cat. No. 0652) joined by a PEG2 linker to the Aurora A inhibitor MK-5108. The compound depletes Aurora A in MV4-11 cell lines and exhibits no degradation of Aurora B at 10 μM. JB 300 shows dose-dependent cytotoxicity in AML cells .

PROTAC™; is a registered trademark of Arvinas Operations, Inc., and is used under license.

Caractéristiques techniques

MarqueTocris Bioscience
Réf. B-LABOBL-RE-157979
Réf. fabricant18706025
Nom chimique ou matériautrans-4-(3-Chloro-2-fluorophenoxy)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethoxy)ethyl)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxamide
Quantité5 mg
CibleActive Degraders
Formule moléculaireC<sub>43</sub>H<sub>45</sub>ClFN<sub>7</sub>O<sub>10</sub>S
Pureté0.98
Une question, une configuration particulière ?
Contactez-nous pour un devis.